Study of Hemospray for Lower Gastrointestinal Hemorrhage
A Prospective Observational Cohort Study of Hemospray for Lower Gastrointestinal Hemorrhage (APPROACH LGI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada
- Royal Alexandra Hospital
-
Edmonton, Alberta, Canada
- University of Alberta Hospital
-
-
Ontario
-
Kingston, Ontario, Canada
- Hotel Dieu Hospital
-
-
Quebec
-
Montreal, Quebec, Canada
- Montreal General Hospital - McGill University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient in which Hemospray is used to treat an endoscopically confirmed nonvariceal lower GI bleed requiring hemostasis
Exclusion Criteria:
- Less than 19 years old
- Unwilling or unable to sign and date the informed consent
- Pregnant, lactating or planning to become pregnant within 30 days of the procedure
- Contraindicated to undergo colonoscopy
Medical/Endoscopic Exclusion Criteria
- Actual or suspected lower GI perforation or fistula
- Bleeding originating from inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
- Actual or suspected ischemic colitis or infectious colitis
- Unable to visualize site of active bleeding (such as suspected diverticular bleed where source is unable to be identified)
- Unable to treat active site of bleeding (e.g., bleeding site cannot be reached by the colonoscope)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Hemospray to treat lower GI bleeds
|
The Hemospray™ device comes in a 7F kit and a 10F kit.
Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material.
Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of device related adverse events
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of recurrent bleeding that occurs outside the blood vessel
Time Frame: 30 days
|
30 days
|
|
|
Percentage of hemostasis of lower GI bleeds originating from multiple sources
Time Frame: 30 days
|
30 days
|
|
|
All cause mortality
Time Frame: 30 days
|
Mortality within 30 days of index procedure
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Intestinal Diseases
- Pathological Conditions, Anatomical
- Polyps
- Intestinal Polyps
- Diverticular Diseases
- Hemorrhage
- Colonic Polyps
- Gastrointestinal Hemorrhage
- Diverticulum
- Diverticulosis, Colonic
- Diverticulum, Colon
- Angiodysplasia
Other Study ID Numbers
Other Study ID Numbers
- 12-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.